2.15
price down icon5.70%   -0.13
after-market Handel nachbörslich: 2.15
loading
Schlusskurs vom Vortag:
$2.28
Offen:
$2.26
24-Stunden-Volumen:
1.28M
Relative Volume:
0.74
Marktkapitalisierung:
$128.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.80M
KGV:
-2.8667
EPS:
-0.75
Netto-Cashflow:
$-30.67M
1W Leistung:
-3.15%
1M Leistung:
-20.07%
6M Leistung:
-56.12%
1J Leistung:
-42.36%
1-Tages-Spanne:
Value
$2.10
$2.26
1-Wochen-Bereich:
Value
$2.10
$2.30
52-Wochen-Spanne:
Value
$1.14
$7.20

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name
Firmenname
Aldeyra Therapeutics Inc
Name
Telefon
781-761-4904
Name
Adresse
131 HARTWELL AVENUE, LEXINGTON, MA
Name
Mitarbeiter
8
Name
Twitter
@aldeyraaldx
Name
Nächster Verdiensttermin
2024-11-18
Name
Neueste SEC-Einreichungen
Name
ALDX's Discussions on Twitter

Vergleichen Sie ALDX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALDX
Aldeyra Therapeutics Inc
2.15 132.97M 0 -44.80M -30.67M -0.75
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-04-03 Hochstufung Oppenheimer Perform → Outperform
2024-04-02 Fortgesetzt H.C. Wainwright Buy
2022-04-27 Fortgesetzt H.C. Wainwright Buy
2021-02-08 Eingeleitet H.C. Wainwright Buy
2020-12-16 Eingeleitet Berenberg Buy
2020-10-30 Eingeleitet Jefferies Buy
2020-10-16 Eingeleitet BTIG Research Buy
2020-09-22 Eingeleitet Alliance Global Partners Buy
2020-05-12 Eingeleitet Oppenheimer Outperform
2018-12-04 Eingeleitet Citigroup Buy
2018-09-26 Bestätigt Cantor Fitzgerald Overweight
2018-09-13 Eingeleitet Janney Buy
2018-01-26 Eingeleitet Seaport Global Securities Buy
2016-09-26 Eingeleitet H.C. Wainwright Buy
2016-07-01 Eingeleitet Stifel Buy
2015-07-01 Eingeleitet Canaccord Genuity Buy
2015-03-25 Eingeleitet Chardan Capital Markets Buy
2015-03-20 Bestätigt H.C. Wainwright Buy
2014-11-18 Eingeleitet H.C. Wainwright Buy
2014-06-19 Eingeleitet Aegis Capital Buy
Alle ansehen

Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten

pulisher
May 29, 2025

Trading (ALDX) With Integrated Risk Controls - news.stocktradersdaily.com

May 29, 2025
pulisher
May 29, 2025

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference | ALDX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference - Business Wire

May 29, 2025
pulisher
May 26, 2025

Northern Trust Corp Purchases 16,894 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 26, 2025
pulisher
May 25, 2025

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Acquired by Deutsche Bank AG - Defense World

May 25, 2025
pulisher
May 24, 2025

D. E. Shaw & Co. Inc. Sells 146,198 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 24, 2025
pulisher
May 23, 2025

Q3 Earnings Forecast for ALDX Issued By Leerink Partnrs - Defense World

May 23, 2025
pulisher
May 22, 2025

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven? - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

HC Wainwright Has Strong Forecast for ALDX FY2029 Earnings - Defense World

May 22, 2025
pulisher
May 22, 2025

Q2 EPS Estimate for Aldeyra Therapeutics Lifted by Analyst - Defense World

May 22, 2025
pulisher
May 21, 2025

Aldeyra Therapeutics (NASDAQ:ALDX) Raised to “Sell” at StockNews.com - Defense World

May 21, 2025
pulisher
May 20, 2025

Balyasny Asset Management L.P. Acquires New Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 20, 2025
pulisher
May 20, 2025

Aldeyra Therapeutics (NASDAQ:ALDX) Given “Buy” Rating at HC Wainwright - Defense World

May 20, 2025
pulisher
May 19, 2025

ALDX: HC Wainwright & Co. Reiterates Buy Rating with $10 Target | ALDX Stock News - GuruFocus

May 19, 2025
pulisher
May 18, 2025

(ALDX) Trading Report - news.stocktradersdaily.com

May 18, 2025
pulisher
May 18, 2025

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - FinancialContent

May 18, 2025
pulisher
May 18, 2025

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock Holdings Lessened by Price T Rowe Associates Inc. MD - Defense World

May 18, 2025
pulisher
May 14, 2025

Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical ... - Eagle-Tribune

May 14, 2025
pulisher
May 14, 2025

Bragar Eagel & Squire, P.C. Is Investigating Organon, - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Aldeyra Therapeutics, Inc. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 13, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra - Bluefield Daily Telegraph

May 13, 2025
pulisher
May 13, 2025

Hsbc Holdings PLC Acquires Shares of 10,457 Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 13, 2025
pulisher
May 12, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire

May 12, 2025
pulisher
May 11, 2025

SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

May 11, 2025
pulisher
May 11, 2025

Barclays PLC Has $376,000 Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 11, 2025
pulisher
May 08, 2025

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, - GlobeNewswire

May 08, 2025
pulisher
May 07, 2025

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical ... - Eagle-Tribune

May 07, 2025
pulisher
May 07, 2025

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm - TradingView

May 07, 2025
pulisher
May 07, 2025

Aldeyra Therapeutics Drops To US$2.10, Yet Insiders May Have Sold Too Early - simplywall.st

May 07, 2025
pulisher
May 07, 2025

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

Aldeyra makes third run at FDA approval for dry eye drug - The Pharma Letter

May 07, 2025
pulisher
May 06, 2025

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data - insights.citeline.com

May 06, 2025
pulisher
May 06, 2025

Aldeyra DED phase III hits but reproxalap field goal fumbled - BioWorld MedTech

May 06, 2025
pulisher
May 06, 2025

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire

May 06, 2025
pulisher
May 06, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc.(ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline - Barchart.com

May 06, 2025
pulisher
May 06, 2025

SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

May 06, 2025
pulisher
May 06, 2025

Aldeyra plots third FDA filing for dry eye disease drug after latest Phase 3 data - Endpoints News

May 06, 2025
pulisher
May 06, 2025

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Ey - GuruFocus

May 06, 2025
pulisher
May 05, 2025

Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial | ALDX Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Breakthrough in Dry Eye Treatment: Aldeyra's Reproxalap Achieves Significant Phase 3 Results, FDA Filing Next - Stock Titan

May 05, 2025
pulisher
May 05, 2025

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap - Business Wire

May 05, 2025
pulisher
May 05, 2025

ALDX SECURITIES ALERT: Lose Money on Aldeyra Therapeutics, - GlobeNewswire

May 05, 2025
pulisher
May 05, 2025

Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com

May 05, 2025
pulisher
May 05, 2025

Invesco Ltd. Cuts Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 05, 2025
pulisher
May 03, 2025

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) - GlobeNewswire

May 03, 2025
pulisher
May 03, 2025

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law - GlobeNewswire Inc.

May 03, 2025
pulisher
May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025
pulisher
May 02, 2025

Renaissance Technologies LLC Purchases 59,700 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 02, 2025
pulisher
May 01, 2025

ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Ongoing Securities Investigation - TradingView

May 01, 2025
pulisher
May 01, 2025

Aldeyra Therapeutics Inc (ALDX) Stock: Navigating a Year of Stock Volatility - investchronicle.com

May 01, 2025

Finanzdaten der Aldeyra Therapeutics Inc-Aktie (ALDX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):